AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19
AstraZeneca drug cocktail succeeds in late-stage examine to deal with COVID-19
The drug, known as AZD7442, lowered the chance of growing extreme COVID-19 or demise by 50% in sufferers who had been symptomatic for seven days or much less, assembly the primary purpose of the trial.
AstraZeneca’s experimental COVID-19 antibody drug cocktail succeeded in lowering extreme illness or demise in non-hospitalised sufferers in a late-stage examine, the British drugmaker mentioned on Monday.
“An early intervention with our antibody can provide a major discount in development to extreme illness, with continued safety for greater than six months,” mentioned Mene Pangalos, govt VP, biopharmaceuticals R&D at AstraZeneca.
The corporate will focus on the info with well-being authorities, it added, without elaborating.
AstraZeneca can be growing the drug cocktail as a remedy to guard individuals who would not have a powerful sufficient immune response to COVID-19 vaccines. It requested emergency approval from US regulators for its use as a prevention drug final week.
